Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma

BACKGROUND: Targeting human epidermal growth factor receptor 2 (HER2) with trastuzumab in metastatic esophagogastric adenocarcinoma (EGA) improves survival. The impact of HER2 inhibition in combination with chemoradiotherapy (CRT) in early stage EGA is under investigation. This study analyzed the pa...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Gastrointest Oncol
Päätekijät: Chan, Ellie, Duckworth, Lizette Vila, Alkhasawneh, Ahmad, Toro, Tania Zuluaga, Lu, Xiaomin, Ben-David, Kfir, Hughes, Steven J., Rossidis, Georgios, Zlotecki, Robert, Lightsey, Judith, Daily, Karen C., Dang, Long, Allegra, Carmen J., King, Brent, George, Thomas J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AME Publishing Company 2016
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4783750/
https://ncbi.nlm.nih.gov/pubmed/27034783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.071
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia